Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
SanDisk's Inclusion in Nasdaq 100 Boosts Stock Price to New High, SNDK Surges 14% in a Day Leading to Significant Long Liquidation on-chain

SanDisk's Inclusion in Nasdaq 100 Boosts Stock Price to New High, SNDK Surges 14% in a Day Leading to Significant Long Liquidation on-chain

BlockBeatsBlockBeats2026/04/14 06:14

BlockBeats News, April 14th, last Friday, an exchange announced that Sandisk (SNDK) will be formally included in the Nasdaq 100 Index constituent stocks before the opening on April 20, 2026.


Boosted by the continued fermentation of this news, SNDK recorded a cumulative increase of over 14% during Monday's intraday and today's after-hours trading, with the stock price hitting a new all-time high. On the Hyperliquid platform, the SNDK contract surged above $980, with a 24-hour increase of 13.8%.


According to Hyperinsight monitoring, the strong market performance has led to all on-chain long positions turning profitable. Among them, "Trader CBB," who has been focusing on shorting US stocks for a long time, shifted to establishing long positions in SNDK since April 6 and has made it his primary holding. The current position size is $6.73 million with a floating profit of $730,000, making him the largest long position on SNDK on Hyperliquid.


0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Chinese 3D vision AI startup Sensing4D AI submits IPO application to US stock market: plans to raise $35 million and advance embodied intelligence simulation.

Sensing4D AI plans to go public on Nasdaq, aiming to raise $35 million, with a primary focus on 3D reconstruction and embodied intelligence simulation. The company's annual revenue is $29 million.

智通财经•2026/10/23 08:57

Rezera (RZRA.US) submits IPO application: Oral NLRP3 inhibitor pipeline progresses, Phase 3 PAD trial scheduled to begin in 2027

Rezera plans to go public on Nasdaq to raise 100 millions USD. Its oral NLRP3 inhibitor will initiate a Phase III trial for PAD, with data expected in 2028.

智通财经•2026/10/23 08:32